


Contents lists available at ScienceDirect

Vaccine





Corrigendum

Corrigendum to "Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines" [Vaccine 34 (2016) 757–761]



Pierre Van Damme ^{a,*}, Paolo Bonanni ^b, F. Xavier Bosch ^c, Elmar Joura ^d, Susanne Krüger Kjaer ^e, Chris J.L.M. Meijer ^f, Karl-Ulrich Petry ^g, Benoit Soubeyrand ^h, Thomas Verstraeten ⁱ, Margaret Stanley ^j

- ^a Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium
- ^b Department of Health Sciences, University of Florence, Florence, Italy
- ^c Cancer Research Epidemiology Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain
- ^d Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
- e Department of Gynaecology, Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and the University of Copenhagen, Copenhagen, Denmark
- ^f Department of Pathology, Free University Medical Center, Amsterdam, The Netherlands
- g Department of Gynaecology and Obstetrics, Klinikum Wolfsburg, Wolfsburg, Germany
- h Sanofi Pasteur MSD, Department of Medical Affairs, Lyon, France
- ⁱ P95, Epidemiology and Pharmacovigilance Consulting and Services, Leuven, Belgium
- ^j Department of Pathology, Cambridge University, Cambridge, UK

The authors regret that an error occurred in Table 1 and the text "no evidence" should be replaced by "incomplete". The corrected version of Table 1 is reproduced below.

The authors would like to apologise for any inconvenience caused.

^{*} Corresponding author. Tel.: +32 32652538; fax: +32 32652640. E-mail address: pierre.vandamme@uantwerp.be (P. Van Damme).

Table 1Scenarios and proposed approaches, for girls 9–14 years of age.

Coors::-	Month	Month	Month	Month	Mosth	Evnostod
Scenario		Month	Month	Month	Month	Expected
	0	2	6	12	18	protection*
Sequentia		administ				
Α	2vHPV		2vHPV			2 types
	2vHPV		2vHPV	9vHPV	9vHPV	2 types and
						likely
						protection for
						the 7 extra
						types
	4vHPV		4vHPV			4 types
	4vHPV		4vHPV	9vHPV	9vHPV	4 types and
	401160		4VIIF V	SVIIFV	SVIIFV	likely
						protection for
						the 5 extra
						types
В	2vHPV	2vHPV				Incomplete
	2vHPV	2vHPV	9vHPV			2 types
	2vHPV	2vHPV	9vHPV	9vHPV		2 types and
						likely
						protection for
						the 7 extra
						types
	4vLIDV	4v/LIDV				
	4vHPV	4vHPV	OverLIDV			Incomplete
	4vHPV	4vHPV	9vHPV	0 1:5:		4 types
	4vHPV	4vHPV	9vHPV	9vHPV		4 types and
						likely
						protection for
						the 5 extra
						types
С	2vHPV					Incomplete
_	2vHPV		9vHPV			2 types
	2vHPV		9vHPV	9vHPV		2 types and
	ZVIIIV		JVIII V	JVIIIV		likely
						protection for
						the 7 extra
						types
	4vHPV					Incomplete
	4vHPV		9vHPV			4 types
	4vHPV		9vHPV	9vHPV		4 types and
						likely
						protection for
						the 5 extra
						types
						ι, ρυσ
Davessi	tion.	I	<u> </u>	L	l	
Revaccina		0 1404	0 1:50:			2.
D	2vHPV	2vHPV	2vHPV			2 types
	2vHPV	2vHPV	2vHPV	9vHPV	9vHPV	2 types and
						likely
						protection for
						the 7 extra
						types
	4vHPV	4vHPV	4vHPV			4 types
	4vHPV	4vHPV	4vHPV	9vHPV	9vHPV	4 types and
	TVIIIV	TVIIIV	TVIIIV	JVIIIV	JVIIIV	likely
						,
						protection for
						the 5 extra
						types
: already received : additional						
,						

^{*:} expected according to currently available data and expert judgment, the role of cross-protection provided by the bi- and quadrivalent was ignored.